0000000000086378

AUTHOR

Michele Massimo Gulizia

showing 4 related works from this author

ANMCO/ELAS/SIBioC Consensus Document: Biomarkers in heart failure

2017

Abstract Biomarkers have dramatically impacted the way heart failure (HF) patients are evaluated and managed. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacological responses to a therapeutic intervention. Natriuretic peptides [B-type natriuretic peptide (BNP) and N-terminal proBNP] are the gold standard biomarkers in determining the diagnosis and prognosis of HF, and a natriuretic peptide-guided HF management looks promising. In the last few years, an array of additional biomarkers has emerged, each reflecting different pathophysiological processes in the development and progression of HF: …

medicine.drug_classFibrosiGalectin 3Heart failure030204 cardiovascular system & hematologyBioinformatics03 medical and health sciences0302 clinical medicineFibrosismedicineNatriuretic peptideNatriuretic peptides030212 general & internal medicineBiomarkers; Fibrosis; Galectin 3; Heart failure; Inflammation; Natriuretic peptides; Troponin; Cardiology and Cardiovascular MedicinePathologicalInflammationbiologybusiness.industryArticlesBiomarkermedicine.diseaseBrain natriuretic peptideFibrosisTroponinTroponinGalectin-3Heart failurebiology.proteinBiomarker (medicine)businessCardiology and Cardiovascular MedicineBiomarkers; Fibrosis; Galectin 3; Heart failure; Inflammation; Natriuretic peptides; TroponinBiomarkersNatriuretic peptide
researchProduct

Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study

2020

Background and aims: Familial hypercholesterolaemia (FH) is a powerful risk factor for cardiovascular (CV) events. High levels of low-density lipoprotein cholesterol (LDL-C) since birth are linked to the early onset of atherosclerotic disease. A genetic mutation determining FH is present in about one subject out of 250; FH should be more represented among subjects with a documented diagnosis of coronary artery disease (CAD). The POSTER Study evaluated the prevalence of FH in Italian patients with a recent CAD event. Methods: Eighty-two cardiology centres enrolled patients with a documented CAD event; CV risk profile, drug therapy and biochemical parameters were collected. Dutch Lipid Clinic…

Male0301 basic medicineAcute coronary syndromemedicine.medical_specialtySettore MED/09 - Medicina InternaFamilial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyCoronary revascularizationCoronary artery diseaseHyperlipoproteinemia Type IICoronary artery disease03 medical and health sciences0302 clinical medicinePharmacotherapyRisk FactorsInternal medicinePrevalencemedicineHumansLow-density lipoprotein cholesterolMyocardial infarctionRisk factorAgedHigh prevalencebusiness.industryCholesterol LDLMiddle Agedmedicine.diseaseCoronary revascularizationMyocardial infarction030104 developmental biologyItalyDutch lipid clinic networkCardiology and Cardiovascular MedicinebusinessAtherosclerosis
researchProduct

ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiova…

2017

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

medicine.medical_specialtySettore MED/09 - Medicina InternaPCSK9 inhibitorMEDLINE030204 cardiovascular system & hematologyNOatherosclerosis; diagnostic and therapeutic pathways; hypercholesterolaemia; PCSK9 inhibitors; statins; sustainable health careDiagnostic and therapeutic pathways03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicine030212 general & internal medicineIntensive care medicineRisk managementCause of deathHypercholesterolaemiabusiness.industryAtherosclerotic cardiovascular diseaseCholesterolSustainable health careStatinsDiagnostic and therapeutic pathwayStatinHigh Cholesterol LevelsArticlesmedicine.diseaseAtherosclerosischemistryPCSK9 inhibitorsAtherosclerosiCardiologylipids (amino acids peptides and proteins)Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal Supplements : Journal of the European Society of Cardiology
researchProduct

Documento di consenso intersocietario ANMCO/ISS/AMD/ANCE/ARCA/FADOI/ GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/ SID/SIF/SIMEU/SIMG/SIMI/SISA Colesterolo …

2016

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

Settore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaSettore MED/09 - Medicina InternaItalyCardiovascular DiseaseRisk FactorAnticholesteremic AgentHypercholesterolemiaSettore BIO/14 - FarmacologiaConsensuCardiology and Cardiovascular MedicineSettore MED/11 - Malattie Dell'Apparato CardiovascolareHuman
researchProduct